IMP321, a LAG-31g fusion protein, completed Phase I/II study in breast cancer.
Firm claims HiPEG interferon demonstrates eight-fold higher activity than marketed product.
A therapeutic protein or monoclonal antibody (mAb) can be turned into an effective therapy and a revenue-generating product only if it can be efficiently filtered from the process stream. If a product is inefficiently...
Kits will be incorporated into analysis of FFPE patient samples using Symphony breast cancer diagnostics.
Source: Newcastle University Researchers at Newcastle University report a significant advance in the continuous production and collection of cells. The process removes the limit on the number of cells that can be grown in a culture dish, which...
Lilly will in-license 10 branded generic injectable and oral cancer medicines from Agila.
Protein engineering work improves a naturally occurring enzyme's ability to degrade polyethylene terephthalate (PET), one of the most abundantly produced synthetic polymers
EDI200 is being investigated as a treatment for X-linked hypohidrotic ectodermal dysplasia.
Firm will use the cell line to produce Humaneered recombinant antibody therapeutics.
Please wait while you are redirected to the right page...